文献速递肝病

慢性肝病与肝硬化患者SARS-CoV-2感染结局:全国COVID队列协作研究

Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.
PubMed 文献 · Gastroenterology · 2021-07-18

肝硬化/阳性患者30天全因死亡率为8.9%,校正后死亡风险分别为肝硬化/阴性患者的2.38倍和非肝硬化/阳性患者的3.31倍。

要点

  • 肝硬化患者感染SARS-CoV-2后30天死亡风险显著升高,校正HR为2.38。
  • 在感染SARS-CoV-2的慢性肝病患者中,合并肝硬化使30天死亡风险增至3.31倍。
  • 高龄、肥胖及合并症(糖尿病、心衰、肺病)的肝硬化患者感染后死亡风险进一步增加。

核心结论

  • 肝硬化患者感染SARS-CoV-2与30天死亡风险增加相关,校正风险比为2.38。
  • 在感染SARS-CoV-2的慢性肝病患者中,合并肝硬化与30天死亡风险增加相关,校正风险比为3.31。
  • 结果提示需提高严重肝病患者的疫苗接种率并研究其疫苗免疫应答。

研究设计与样本

  • 纳入截至2021年7月1日在N3C数据飞地中有SARS-CoV-2检测的慢性肝病伴或不伴肝硬化患者。
  • 采用生存分析评估SARS-CoV-2感染、肝硬化及临床因素与30天死亡率的关系。

主要发现

  • 共纳入220,727例慢性肝病患者:非肝硬化/阴性128,864例(58%),非肝硬化/阳性29,446例(13%),肝硬化/阴性53,476例(24%),肝硬化/阳性8,941例(4%)。
  • 30天全因死亡率在肝硬化/阴性患者中为3.9%,在肝硬化/阳性患者中为8.9%。
  • 与肝硬化/阴性患者相比,肝硬化/阳性患者30天校正死亡风险比为2.38。
  • 与非肝硬化/阳性患者相比,肝硬化/阳性患者30天校正死亡风险比为3.31。
  • 在肝硬化患者中,高龄、肥胖及合并症(糖尿病、心衰、肺病)与SARS-CoV-2感染后校正死亡风险增加相关。

临床怎么用

  • 对肝硬化患者应加强SARS-CoV-2感染预防,包括提高疫苗接种率。
  • 对合并高龄、肥胖、糖尿病、心衰或肺病的肝硬化患者,感染后需更密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In patients with chronic liver disease (CLD) with or without cirrhosis, existing studies on the outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have limited generalizability. We used the National COVID Cohort Collaborative (N3C), a harmonized electronic health record dataset of 6.4 million, to describe SARS-CoV-2 outcomes in patients with CLD and cirrhosis. METHODS: We identified all patients with CLD with or without cirrhosis who had SARS-CoV-2 testing in the N3C Data Enclave as of July 1, 2021. We used survival analyses to associate SARS-CoV-2 infection, presence of cirrhosis, and clinical factors with the primary outcome of 30-day mortality. RESULTS: We isolated 220,727 patients with CLD and SARS-CoV-2 test status: 128,864 (58%) were noncirrhosis/negative, 29,446 (13%) were noncirrhosis/positive, 53,476 (24%) were cirrhosis/negative, and 8941 (4%) were cirrhosis/positive patients. Thirty-day all-cause mortality rates were 3.9% in cirrhosis/negative and 8.9% in cirrhosis/positive patients. Compared to cirrhosis/negative patients, cirrhosis/positive patients had 2.38 times adjusted hazard of death at 30 days. Compared to noncirrhosis/positive patients, cirrhosis/positive patients had 3.31 times adjusted hazard of death at 30 days. In stratified analyses among patients with cirrhosis with increased age, obesity, and comorbid conditions (ie, diabetes, heart failure, and pulmonary disease), SARS-CoV-2 infection was associated with increased adjusted hazard of death. CONCLUSIONS: In this study of approximately 221,000 nationally representative, diverse, and sex-balanced patients with CLD; we found SARS-CoV-2 infection in patients with cirrhosis was associated with 2.38 times mortality hazard, and the presence of cirrhosis among patients with CLD infected with SARS-CoV-2 was associated with 3.31 times mortality hazard. These results provide an additional impetus for increasing vaccination uptake and further research regarding immune responses to vaccines in patients with severe liver disease.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ge J, Pletcher MJ, Lai JC, et al. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology. 2021. PMID: 34284037. doi:10.1053/j.gastro.2021.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。